Tom Boone
Oprichter bij REMD Biotherapeutics, Inc.
Profiel
Tom Boone has founded REMD Biotherapeutics, Inc. in 2011, where he holds the title of Chief Scientific Officer.
Currently, he is an Advisor at Ally Bridge Group HK Ltd since 2014.
Mr. Boone completed his undergraduate degree at the University of California, Davis.
Actieve functies van Tom Boone
| Bedrijven | Functie | Begin |
|---|---|---|
REMD Biotherapeutics, Inc.
 REMD Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology REMD Biotherapeutics, Inc. is a clinical-stage biotechnology company that focuses on developing protein-based therapies to treat metabolic diseases and other serious illnesses. The private company was founded in 2011 by two former Amgen research scientists, Yan Hai and Tom Boone, and is based in Camarillo, CA, with additional facilities in Beijing. REMD Biotherapeutics has established several unique antibody research and development platforms, including a G protein-coupled receptors (GPCRs) antibody platform, a Synermab bispecific antibody platform, and a tumor-activating interferon (TAI) bifunctional antibody interferon fusion platform. The company's most advanced program is volagidemab (REMD-477), a fully human antibody that has completed phase 2 clinical studies in type 1 and type 2 diabetes and is in preparation for initiating multi-center clinical phase 3 studies in type 1 diabetes. | Oprichter | 01-01-2011 |
Ally Bridge Group HK Ltd
 Ally Bridge Group HK Ltd Investment ManagersFinance Ally Bridge Group HK Ltd (Ally Bridge) is a private equity firm founded in 2011 by Frank Yu. The firm is headquartered in Hong Kong with additional office in the US. | Consultant / Adviseur | 01-01-2014 |
Opleiding van Tom Boone
| University of California, Davis | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 2 |
|---|---|
Ally Bridge Group HK Ltd
Ally Bridge Group HK Ltd Investment ManagersFinance Ally Bridge Group HK Ltd (Ally Bridge) is a private equity firm founded in 2011 by Frank Yu. The firm is headquartered in Hong Kong with additional office in the US. | Finance |
REMD Biotherapeutics, Inc.
REMD Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology REMD Biotherapeutics, Inc. is a clinical-stage biotechnology company that focuses on developing protein-based therapies to treat metabolic diseases and other serious illnesses. The private company was founded in 2011 by two former Amgen research scientists, Yan Hai and Tom Boone, and is based in Camarillo, CA, with additional facilities in Beijing. REMD Biotherapeutics has established several unique antibody research and development platforms, including a G protein-coupled receptors (GPCRs) antibody platform, a Synermab bispecific antibody platform, and a tumor-activating interferon (TAI) bifunctional antibody interferon fusion platform. The company's most advanced program is volagidemab (REMD-477), a fully human antibody that has completed phase 2 clinical studies in type 1 and type 2 diabetes and is in preparation for initiating multi-center clinical phase 3 studies in type 1 diabetes. | Health Technology |
